Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study by Igor V. Samoylenko, Igor V. Samoylenko, Yulia M. Kolontareva, Ekaterina V. Kogay, Ekaterina V. Kogay, Natalia V. Zhukova, Igor A. Utyashev, Mikhail E. Ivannikov, Konstantin V. Menshikov, Maxim V. Zinkevich, Kristina V. Orlova, Kristina V. Orlova, Yulia V. Vakhabova, Mikhail V. Volkonsky, Natalia A. Beliaeva, Ivan I. Butkov, Elena V. Karabina, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Vitaliy D. Sychev, Oxana S. Cheplukhova, Vera V. Chernova, Alexandr N. Yurchenkov, Ksenia G. Babina, Nikita A. Savelov, Lev V. Demidov, Lev V. Demidov

Get full text